<p style=”margin: 0px 0px 6px; color: #141823; font-family: Helvetica, Arial, ‘lucida grande’, tahoma, verdana, arial, sans-serif; font-size: 14px;”>Excellent news from ASH (American of Hematology) meeting in San Francisco. Adding carfilzomib (Kyprolis) to Revlimid and dex for first relapse increases progression-free survival by 9 months and has other benefits too. See Keith Stewart talking about the ASPIRE trial at the video link here</p>
http://ecancer.org/video/3339/aspire-study–carfilzomib-potent-addition-to-multiple-myeloma-therapy.php
<p style=”margin: 6px 0px 0px; display: inline; color: #141823; font-family: Helvetica, Arial, ‘lucida grande’, tahoma, verdana, arial, sans-serif; font-size: 14px;”>and hear “myeloma highlights from ASH” here
http://ecancer.org/video/3361/ash-2014–highlights-in-multiple-myeloma.php</p>
